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Abstract
AntiJen is a database system focused on the integration of kinetic, thermodynamic, functional, and
cellular data within the context of immunology and vaccinology. Compared to its progenitor
JenPep, the interface has been completely rewritten and redesigned and now offers a wider variety
of search methods, including a nucleotide and a peptide BLAST search. In terms of data archived,
AntiJen has a richer and more complete breadth, depth, and scope, and this has seen the database
increase to over 31,000 entries. AntiJen provides the most complete and up-to-date dataset of its
kind. While AntiJen v2.0 retains a focus on both T cell and B cell epitopes, its greatest novelty is
the archiving of continuous quantitative data on a variety of immunological molecular interactions.
This includes thermodynamic and kinetic measures of peptide binding to TAP and the Major
Histocompatibility Complex (MHC), peptide-MHC complexes binding to T cell receptors,
antibodies binding to protein antigens and general immunological protein-protein interactions. The
database also contains quantitative specificity data from position-specific peptide libraries and
biophysical data, in the form of diffusion co-efficients and cell surface copy numbers, on MHCs and
other immunological molecules. The uses of AntiJen include the design of vaccines and diagnostics,
such as tetramers, and other laboratory reagents, as well as helping parameterize the bioinformatic
or mathematical in silico modeling of the immune system. The database is accessible from the URL:
http://www.jenner.ac.uk/antijen.
Introduction
There is a vast, and ever increasing, volume of important
information that has accumulated from decades of exper-
imental analysis within immunology. This will only
become compounded as high-throughput techniques
begin to impinge upon the immunological biosciences.
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The only efficient way for this information to be properly
utilized requires the development of databases that store
it and systems that use it. Although the type of data
archived may alter from case to case, nonetheless the cre-
ation, use, and manipulation of databases containing bio-
logically important information is the most crucial feature
of current bioinformatics, both as it supports the genomic
and post-genomic revolutions and as a discipline in its
own right. There is nothing new in developing databases
focusing on immunology: many spotlighting the in-depth
sequence analysis of individual immunomacromolecules
have existed for some time [1]. Functional or epitope-ori-
entated databases are a more recent development. Exam-
ples include the now defunct MHCPEP database [2]http:/
/wehih.wehi.edu.au/mhcpep/, FIMM [3]http://
sdmc.krdl.org.sg:8080/fimm, SYFPEITHI [4]http://
www.syfpeithi.de, the HIV sequence database [5]http://
hiv-web.lanl.gov/, the HLA ligand database [6]http://hla
ligand.ouhsc.edu, the EPIMHC database [7]http://
bio.dfci.harvard.edu/epimhc/, and the MHCBN database
[8]http://www.imtech.res.in/raghava/mhcbn/.
An epitope is any molecular structure that can be recog-
nised by the immune, or other biological, system.
Epitopes, or the antigen from which they are derived, can
be composed of protein, carbohydrate, lipid, nucleotide,
or a combination thereof. It is through recognition of for-
eign, or non-self, epitopes that the immune system can
identify and, hopefully, destroy pathogens. Hitherto, pep-
tide epitopes have been the best studied, and have, tradi-
tionally, have been categorized as either T cell or B cell
epitopes. T cell epitopes are peptides presented to the cel-
lular arm of the immune system via the MHC-peptide-
TCR complex. B cell epitopes represent surface regions of
an antigen that are bound by soluble or membrane-
bound antibodies. If this region of a protein antigen is
comprised of residues distally separated within the pri-
mary structure, and brought into local proximity by pro-
tein folding, then it is termed a discontinuous or
conformational B cell epitope. Linear or continuous B cell
epitope residues are sequential in both primary structure
and thus as a region on the proteins' surface. Such
epitopes are predominantly identified by antigen-specific
antibody cross-reactivity with peptides.
There is a need to create a databank for the wider disci-
plines of immuno-vaccinologists, which can act as a cen-
tral repository and resource. Our aim is to complement
other databanks [2-8] and thus we have developed Anti-
Jen, a computational information resource for immunol-
ogy and vaccinology that integrates quantitative kinetic,
thermodynamic and biophysical data, with functional
and cellular information. AntiJen v2.0, a development of
our earlier database system JenPep [9,10], contains func-
tional data on T cell and B cell epitopes. Moreover, the B
cell archive is now sub-divided into linear and conforma-
tional epitopes. These epitopes form the basis of the
humoral immune response and, unlike T cell epitopes,
methods of prediction are often inaccurate [11]. A more
in-depth B cell epitope archive should aid the develop-
ment of prediction strategies. Antigen recognition by the
Major Histocompatibility Complex (MHC) is vital to T
cell activation hence, the inclusion of thermodynamic
data on the binding of peptides to MHC molecules and T
Cell Receptor (TCR) binding to peptide-MHC (pMHC)
complexes. This data is complemented by kinetic data
based on the same molecular interactions. Data on anti-
gen processing and presentation is also included in Anti-
Jen. Binding data derived from peptide interactions with
the Transporter Associated with Antigen Processing (TAP
transporter) are included in the archive. Additionally,
quantitative specificity data from position-specific pep-
tide libraries is included. AntiJen also incorporates ther-
modynamic data on protein-protein interactions, within
an immunological context, such as co-receptor and super-
antigen binding, plus interactions with the MHC. All of
these interactions are, potentially, key factors for the suc-
cessful computational design of vaccines.
AntiJen also contains biophysical data, including diffu-
sion coefficients and cell surface copy numbers, on a vari-
ety of immunological molecules. Such data provides
insight into the number of target receptors, which is an
important, if under explored, component of binding
between cells. Indeed, the number of molecules expressed
on the membrane can alter depending on disease. The
final addition to the databank focuses upon antigen bind-
ing to antibodies. One key innovation is a greatly
increased compendium of experimental conditions,
which, in conjunction with a greatly enhanced search
capacity, consolidates our databases as a unique, value-
added data source, fostering developments within both in
silico immunology and the wider community of immuno-
vaccinology. The database is available from the URL:
http://www.jenner.ac.uk/antijen.
Database development
Relative to the database system used for JenPep [9,10], the
interface to AntiJen is entirely new, having been com-
pletely rewritten. AntiJen has been designed and imple-
mented using postgreSQL, a system comprising a
relational database and database server, and has thus
established increased database robustness, creating an
improved infrastructure for foreseeable issues of data stor-
age and data growth. Data within AntiJen is structured
into twenty-four normalised tables. Each is category spe-
cific and holds either statistical or experimental data.
Additional tables accommodate the keyword data – which
powers our protein-orientated antigen search and allows
integration of the BLAST search – and there is also aImmunome Research 2005, 1:4 http://www.immunome-research.com/content/1/1/4
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structural data table to accommodate links to external
structural databases. The user interface consists of a series
of HTML forms. The search requests from these forms tar-
get PERL scripts integrated with SQL which in turn query
the database.
Database content
Compared to its progenitor JenPep [9,10], the data
archived in AntiJen v2.0 has grown considerably in depth
(additional data types such as experimental conditions),
breadth (addition of new data to existing databases), and
scope (addition of extra sub-databases containing novel
kinds of information). Additions to AntiJen have been
derived from exhaustive searching of the primary litera-
ture, to give a dataset of > 31,000 entries. AntiJen v2.0 now
consists of 11 sub-databases; details of the different data-
bases are given in Table 1. The relative sizes of the data-
bases and the growth from JenPep are summarised in
Table 2.
AntiJen contains both generic and dataset-specific data.
For each entry, we record the peptide sequence (eg.
YTSDYFISY) of the epitope using the standard one-letter
code, its length (9 in this case), and, by linking to the
sequence database Swiss-Prot http://us.expasy.org/sprot/
or NCBI http://www.ncbi.nih.gov/entrez, the antigen to
which the peptide sequence most closely matches (in the
case of YTSDYFISY: C-ests-1 (p54), SWISS-PROT code
P41156). The description of the antigen is, wherever pos-
sible, obtained directly from the literature. AntiJen is also
linked to PUBMED. This allows us to record the original
citation associated with the data. For example, for YTSDY-
FISY, we cite: Journal of Immunol 1994 volume 152 pages
3913–3924, PUBMED ID 8144960. For the T cell epitope,
MHC ligand, and TCR-pMHC complex categories, we also
record, for each peptide, the MHC restriction in terms of
the host species, class (class I vs. class II), and, where the
data is available, the serotype and allele. For YTSDYFISY,
these data would be human, class I, HLA-A1, and A*0101.
Entries within AntiJen are, in turn, linked to external data-
bases, which enables further in-depth cross referencing. As
we have said, protein sequence identifiers, which may be
the source of an antigenic peptide or immunological co-
receptor, link directly to details in the Swiss-Prot database
[12] or the NCBI protein database. Journal references can
be viewed via a link to the PUBMED database http://
www.ncbi.nlm.nih.gov/pubmed, and thus to full litera-
ture references, where available. AntiJen also links to
structural data, currently derived from the MPID database
http://surya.bic.nus.edu.sg/mpid/[13] and the Protein
Data Bank http://www.rcsb.org/pdb/[14]. The database
aims to provide access to background data where
available.
Allele identifiers serve as a link to the IMGT/HLA database
http://www.ebi.ac.uk/imgt at the European Bioinformat-
ics Institute [15]. Inherent variability in the way MHC
alleles are named within the primary literature  prevents
us from unambiguously standardizing nomenclature
within AntiJen. HLA nomenclature follows that of the
HLA Informatics Group http://www.anthonyno
lan.org.uk/HIG/. An allele is named using a defined pat-
tern. For example, for HLA-A*0101: the HLA-A refers to
the HLA locus; the first 01 to the serologically recognized
A1 antigen and the final 01 to the individual HLA allele
protein sequence. AntiJen stores the antigen classification
(i.e. HLA-A1) and, when available, the specific allele. We
have often encountered problems with the nonstandard
allele reporting. A 4-digit HLA name necessarily implies
the two digit serological antigen, a two digit classification
clearly does not imply a specific allele.
During database compilation, a sequence search allows us
to identify the protein from which an epitope sequence
Table 1: AntiJen sub-databases and content.
DATABASE CONTENT
T Cell Epitopes Contains T Cell epitope peptides (known binders).
B Cell Epitopes Contains B Cell linear and conformational epitope peptides.
MHC-Peptide Binding data relating to antigenic peptides and MHC interactions.
TCR Binding data relating to antigenic peptides – TCR – MHC interactions.
TAP Binding data relating to antigenic peptides and TAP interactions.
Kinetics Kinetic binding data for MHC peptide interactions.
IPPI Binding data for a collection of immunological protein interactions.
Diffusion Coefficient Collection of Diffusion and Friction coefficients for surface peptides.
Copy Number Number/Abundance of cell surface molecules.
Peptide Libraries Relative binding data for antigenic peptide amino acid substitutions.
Antibody-Peptide A variety of antibodies known to bind proteins.Immunome Research 2005, 1:4 http://www.immunome-research.com/content/1/1/4
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originates. However, because epitopes are generally short,
their sequences may be present in several potential anti-
gens: in orthologues, paralogues, or in totally unrelated
sequences. As epitopes are processed from whole proteins
via a complex proteolytic pathway, one can use the
sequence context to infer preferred proteasomal or endo-
plasmic protease cleavage patterns, but not if its context is
defined incorrectly. Moreover, assuming that AntiJen is
used subsequently to assign the antigenic status of pro-
teins, wrongly identifying particular proteins as antigens
can lead to the percolation of annotation errors [16,17].
AntiJen is, where possible, a quantitative database archiv-
ing continuous measures of binding. This is a fundamen-
tal feature of several sub databases, such as the MHC
ligand and pMHC-TCR databases. The binding of an
immunological macromolecule to a peptide or other
biomacromolecule is quantified as are other receptor-lig-
and interactions:
R+L↔RL
Here R is the receptor (an MHC or TCR), L the ligand
(peptide or pMHC), and RL, the receptor-ligand complex
(pMHC or pMHC-TCR complex). The rate of the forward
reaction is proportional to [L] [R]. The rate of the reverse
reaction is proportional to [RL] as no other species are
involved in dissociation. At equilibrium, the forward and
reverse rates are equal, and so using kon and koff as the
respective constants:
kon[R][L] = koff[RL]
Rearranging:
Here KD is the equilibrium dissociation constant, which
represents the concentration of ligand that occupies 50%
of the equilibrium receptor population, and KA is the
equivalent association constant.
Experimentally, the measurement of equilibrium dissoci-
ation constants is often addressed using radio-ligand
binding assays. Saturation radio-ligand binding assays
measure equilibrium binding, at a range of peptide con-
centrations, to establish affinity (Ka) and receptor number
(Bmax). Competitive binding experiments determine bind-
ing at a single labelled ligand concentration in the pres-
ence of a range of concentrations of unlabelled ligand.
AntiJen records a hierarchy of different binding measures
in its different sub-databases. Equilibrium constants are
the most dependable and sit atop this hierarchy. Next
come IC50 values, which can be obtained from a competi-
tive radio-ligand or fluorescence assay. These are the
Fmost commonly reported binding measures.
Values obtained from radio-ligand or fluorescence meth-
ods may be significantly different. IC50 values for a pep-
tide may vary between experiments depending on the
intrinsic affinity and concentration of the standard radi-
olabelled reference peptide, as well as the intrinsic affinity
of the test peptide. IC50 values vary with the equilibrium
dissociation constant, at least within a single experiment.
In practice, the variation in IC50 is often small enough that
values can be compared between experiments. For the
peptide discussed above, YTSDYFISY, the radiolabelled
Table 2: Size of AntiJen relative to JenPep. The number of peptides for each category in the AntiJen database is given, distinguishing 
between class I and class II categories, where appropriate. Growth versus JenPep 1 and 2, the progenitors of AntiJen, is included. For 
certain data categories, most obviously TAP binding data, re-evaluation of the quality of data within JenPep has seen it decrease rather 
than increase, however the expansion of the data is clearly seen.
DATABASE JenPep v1.0 JenPep v2.0 AntiJen v1.0 AntiJen v2.0
Class 1 Class 2 Total Class 1 Class 2 Total Class 1 Class 2 TOTAL Class 1 Class 2 TOTAL
T cell epitotes 1266 795 2061 2060 1158 3218 2247 1578 3825 2402 1585 4158
MHC peptide binding 3196 2652 5848 6411 5925 12336 6853 7772 14625 7304 8114 15454
TAP peptide binding 432 441 408 1106
B cell epitotes 816 1295 3541
TCR – peptide-MHC 49 375 124 594 527 253 782
MHC peptide kinetics 704 243 947 897 294 1150
IPPI 805 2675
Copy Number 161 243 414
Diffusion coefficients 759
Peptide Libraries 897
Antibody 395
[] []
[]
RL
RL
k
k
KK
off
on
DA == = −1Immunome Research 2005, 1:4 http://www.immunome-research.com/content/1/1/4
Page 5 of 12
(page number not for citation purposes)
IC50 value recorded in AntiJen is 5.3 nM. BL50 values are
also obtained from a peptide binding assay and are com-
monly reported. They are the half maximal binding levels
calculated from mean fluorescence intensities of peptides
binding to MHCs bound on the surface of RMA-S or T2
cells. Cells, pre-incubated with peptides, are labelled with
a fluorescent monoclonal antibody. An overview of the
thermodynamic and kinetic binding data within AntiJen
is given in Table 3.
AntiJen also now contains experimental conditions, such
as temperature and pH. A summary of this data is given in
Table 4. The accuracy of data depends greatly upon the
experimental method used. The grouping of data with
respect to specific experimental techniques allows a more
thorough assessment of training sets. Figure 1 shows the
distribution of data for each type of analysis with respect
to each database. The MHC Kinetics and TAP databases
highlight the problems outlined above. The kinetics data-
base contains data determined from over 14 methods
while the TAP database is derived from 4 methods, with
radiolabelled assays accounting for 80% of the data.
The compilation process has highlighted the considerable
inconsistency within the immunological literature regard-
ing the recording of such fundamental data. AntiJen con-
tains, however, a direct, verbatim transcription of data
from the primary literature. As such, we do not attempt, as
a matter of policy, the comprehensive and retrospective
correction of potential errors. To undertake such correc-
tion would only compound any errors, introducing the
kind of percolating inconsistencies so much a feature of
other database systems [16,17]. Further inaccuracies may
stem from our logistic inability to verify data independ-
ently, therefore we must trust those values reported in the
literature.
Subsidiary Databases in AntiJen
The AntiJen database contains a number of sub-databases.
Each of these contains data on different aspects of the bio-
logical function and/or biophysical properties of different
classes of immunomacromolecule. We describe the nature
and content of each sub database below.
Table 3: AntiJen Thermodynamic and Kinetic Data. An overview of the 6 AntiJen databases that provide binding data. It must also be 
noted that several of the databases contain additional data not present in any of the other databanks.
MHC-Peptide Kinetics IPPI TAP pMHC-TCR Antibody TOTAL
IC50 8562 0 247 1000 0 4 9813
KonIC50 0 188 563 0 157 87 995
Koff 0 146 610 0 150 101 1007
KD 359 156 1143 16 227 70 1971
Ka 65 0 37 0 28 132 262
t1/2 02 0 7 7 2 01 4 804 2 7
Table 4: Experimental conditions and associated information archived in AntiJen. Number of recorded experimental conditions stored 
within the AntiJen database. For each condition (temperature, pH, etc.) we show here the number of entries within a particular sub-
database. [Standard] is the concentration of labelled standard peptide in an assay. Likewise, [competitor] is the concentration of 
competitor peptide within a competition assay. [peptide] is the concentration of peptide in a kinetic experiment. The Method 
category refers to a standard procedure used to perform a particular assay. Differences in the number of recorded data, relative to 
figures in Table 1, arise primarily from the omission of key details from particular papers. Archiving of experimental conditions is on-
going.
DATABASE TOTAL pH Temperature [standard] Stand. peptide seq. [competitor] Method [peptide]
MHC Binding 15454 6679 9831 10893 12796 5007 1251
MHC Kinetics 1150 677 1101 1149 606
TAP Binding 1106 22 243 1092 1101 86 981
TCR-pMHC 782 426 632 668
IPPIa 2675 726 1371 2600
Copy Number 414 183 278 414
Peptide Libraries 897 897 897
Diffusion Coefficient 759 321 668 736
Antibody 395 119 115 372Immunome Research 2005, 1:4 http://www.immunome-research.com/content/1/1/4
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The distribution of experimental methods applied within each database Figure 1
The distribution of experimental methods applied within each database. The number of different experimental 
methods and the abundance of data relating to the method is shown within the figures. The 'OTHERS' category refers to meth-
ods for which there is a relatively small number of entries.Immunome Research 2005, 1:4 http://www.immunome-research.com/content/1/1/4
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B Cell Epitopes
Epitopes are the principal chemical moieties recognized
by the immune system. Although the importance of non-
peptide epitopes, such as carbohydrates and lipids, is now
increasingly well understood, peptidic B cell and T cell
epitopes remain the principal tools by which the intricacy
of the immune response can be explored. B cell epitopes
are regions of the surface of a protein, or other biomacro-
molecule, recognized by soluble or membrane-bound
Antibody molecules. In developing AntiJen, we have dis-
carded the contents of our previous B cell archive and con-
structed one de novo. It contains an entirely new data set
with a substantially different data structure. There are two
forms of epitopes: linear and discontinuous. A linear B
cell epitope is composed of a single stretch of sequential
residues. A discontinuous B cell epitope is composed of
sequentially separate residues brought into close proxim-
ity in a conformationally-dependent arrangement. The
data we archive is primarily focused upon linear epitopes.
This is due to the far greater amount of experimental data
available for linear epitopes, which reflects both the rela-
tively facile experiments needed to identify them and an
implicit belief in their utility as potential vaccine epitopes.
By contrast, discontinuous epitopes are thought to be
more prevalent within folded proteins, but are far more
challenging to determine experimentally. The archive
catalogues the sequence of binding peptides, and also
gives the length and source: TTGDVIASS, a 9 amino acid
peptide from Escherichia coli non-fimbrial adhesion. Resi-
dues identified as important in binding to the antibody
are recorded. This may correspond to a whole peptide or
a subsequence, such as TTGDVI in the above example. The
peptides are also categorized in terms of their relative
observed immunodominance. Antibodies host organism
and isotype are recorded. The current B cell epitope
archive contains 3,541 epitopes.
T Cell Epitopes
T cell epitopes are short peptides bound by major histo-
compatibility complexes (MHC) and subsequently recog-
nized by T cells. Epitopes recognized by both CD4+ and
CD8+ T cells are included in the database. Such epitopes
can be identified in many different ways. However, this
diversity of measurement imposes a certain need for con-
sistency, necessitating the requirement for recording a
range of different experimental methods. The archive has
expanded to include 4,158 entries. The entries contain the
epitopes, ranging in length from 4 to 38 amino acids, pep-
tide information, detailing the source, with links to Swiss-
Prot and the corresponding MHC restriction data such as
Serotype, Allele and Class. Additionally, the peptides are
categorized in to groups such as Allergens, Bacterial, Can-
cer, Human, Viral and Self peptides.
MHC – Peptide binding
AntiJen continues to archive quantitative data on the ther-
modynamics of peptide interactions [18,19], and it has
expanded in number and content, with additions such as
experimental conditions, plus specific Standard and Com-
petitor peptide concentrations used in the assays. The cur-
rent archive contains 15,454 entries. The sequence of the
binding peptide, along with the source, plus relevant
MHC restriction data is recorded. The restriction alleles
currently include those from Human, Mouse, Rat, Rhesus
Monkey, Cotton-top Tamarin, and Chimpanzee. AntiJen
contains IC50 values, binding affinity measurements from
competitive binding assays, for which the standard and
competitor peptides and concentrations are recorded,
plus BL50  values, calculated from peptide stabilizing
assays. Where possible, antibodies and the concentrations
used to calculate BL50 values are archived. Additionally,
but on a somewhat smaller scale, equilibrium association
(KA) and dissociation (KD) constants are recorded for pep-
tide-MHC interaction. Melting temperatures (Tm) and sig-
nal wavelength are also recorded; this is the temperature
and wavelength at which 50% of the MHC protein is
denatured as measured by circular dichroism. AntiJen also
records so-called Weak/Non-binders. This indicates that
the peptide has been tested in an MHC restriction assay
and has been found to exhibit a binding affinity, i.e. an
IC50 value > 10,000 nM for a radio-ligand assay, so low
that it can be categorized as inactive.
pMHC-T Cell Receptor interaction
The TCR sub-database contains 782 entries, which records
thermodynamic and kinetic binding data for the interac-
tion of peptide-MHC (pMHC) complexes with TCRs. Dif-
ferent MHCs exhibit a distinct selectivity for certain
peptide sequences. T cell receptors, in their turn, also
exhibit different affinities for peptide-MHC complexes.
The entries contain epitope, peptide source and MHC
restriction data, as described above, plus TCR structure
information, located at the MMBD database http://
www.ncbi.nlm.nih.gov/Structure/index.shtml. Further-
more, any mutations are noted and a designated name for
the TCR is archived. In addition, the peptides are recorded
as either agonists or antagonists. The binding data is given
as equilibrium constants (KD), EC50 values, rate of associ-
ation (Kon), rate of dissociation (Koff), association con-
stant (KA) and the half-life (t1/2) of the TCR-peptide
interaction.
TAP Binding
This dataset contains binding data for the interactions
between peptides and the TAP transporter, one of the
principle steps in antigen presentation. As with the pep-
tide-MHC database, the data is established from competi-
tor binding experiments, based on labelled assays.
Therefore, standard and competitor peptide sequencesImmunome Research 2005, 1:4 http://www.immunome-research.com/content/1/1/4
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and their concentrations are recorded. The binding data is
given as IC50 and KD values. The database currently con-
tains 1,106 entries, with peptides from Human, Rat and
Mouse sources. Based on IC50 values > 10,000 nM, the
peptides are categorized as weak/non-binders. The entries
have increase in number from the level found in JenPep,
although several entries were removed in an effort to
increase the accuracy and consistency of the archive (Table
2).
Peptide-MHC Kinetics
AntiJen's kinetics sub-database, which contains 1,150
entries, mostly relates to Class I MHC data. It records
measurements for forward and reverse rate constants for
complexation events. This complements the thermody-
namic measurements on peptide-MHC binding described
above. The data currently focuses upon both the half-lives
of binding interactions, as well as association and dissoci-
ation rate constant values (Kon and Koff) for the recorded
epitopes. Additionally, concentrations of the peptide,
MHC and TAP are archived. The half-life for radioisotope
labelled  β2-microglobulin dissociation from an MHC
class I complex, as measured at 37°C, is also archived.
This is a kinetic measurement rather than a thermody-
namic one, although it is often assumed that the greater
the half-life the stronger the peptide-MHC complex. The
half-life (t1/2) equals:
Here the t1/2 corresponds to the dissociation of the MHC-
β2 microglobulin complex rather than the kinetics of the
protein-ligand interaction, but is still peptide dependent,
as well as kinetic in nature.
Immunological Protein-Protein Interactions
The immune system is built around protein interactions
therefore we developed another new sub-database which
deals with Immunological Protein-Protein Interactions
(IPPI). This archive contains 2,675 entries based on a vari-
ety of binding data, such as Kon and Koff rates, for a range
of macromolecules implicated in physiological or patho-
logical interactions, as well as KD, KA and IC50 values. The
molecules include receptors such as CD4 or CD8 mole-
cules, superantigens and other microbial virulence factors,
cytokine receptors and cell adhesion molecules. The
entries detail both protein partners involved in the bind-
ing interaction, with links provided to the NCBI-Entrez
database. Additional data for MHC receptors is archived,
whereby the reactive epitope is recorded and the co-recep-
tors are categorized into viral, bacterial and self peptides.
MHC data outlined in the previous databases is given,
where appropriate including any mutations to the MHC.
Antibody – Protein Binding
AntiJen also contains a further sub-database, which com-
prises thermodynamic data relating to antibody-antigen
binding. The dataset contains 395 entries for antigen pro-
teins and antibodies, mostly derived from viral and mam-
malian sources. Reported values were obtained using
radiolabelled assays and BIAcore analysis. This archive
should aid in the selection of antibodies and peptides for
in vitro studies. The entries list the antibodies and the
binding/kinetic data, consisting of KD and KA values and
to a lesser extent Kon, Koff and IC50 values.
Peptide Libraries
This archive further complements our MHC binding data-
bases by indicating the relative contribution of residues
within peptide libraries to MHC binding. 897 entries con-
tain quantitative specificity data derived from position
specific peptide libraries [20]. This catalogues the relative
effect on affinity, in the form of IC50, log relative SD50 and
log SI values, of all substitutions, at all peptides positions,
against a random sequence backdrop. All of the libraries
relating to a known peptide binder are designated a name
within AntiJen, this usually consists of the author and year
of publication. The archive contains the core peptide,
along with the mutation position and the substituted
amino acid. The corresponding MHC data is given as
mentioned above.
Diffusion Co-efficients
To further increase the range of data archived, AntiJen also
contains 759 records of cellular biophysical data, in the
form of diffusion co-efficients, recorded as cm2s-1, for a
diversity of cell surface molecules, including MHCs
(Mouse and Human), viral peptides and other receptors
[21]. The molecules are either chemically or fluorescently
labelled and then measured using one of two methods:
Single Particle Tracking (SPT) or Fluorescence Photob-
leaching Recovery (FPR). SPT monitors the lateral motion
of a labelled molecule while FPR measures the rate of sub-
sequent infiltration from a photobleached section of the
membrane. Friction co-efficient data is also given, which
measures of the velocity and force applied to an antibody-
coated bead. Records contain the cell or cell type where
diffusion is occurring, the name of the diffusing protein
along with the form of labelling applied. Furthermore,
specific experimental data is given such as antibody bead
size. In this case the diffusion of the beads is monitored.
Increasingly, data relating to photobleaching is included,
such as beam power, bleaching duration, pre- and post-
bleach time, etc..
Copy Numbers
The final sub-database contains 414 measures of cell sur-
face populations of different molecules, called cell surface
copy numbers hereafter. This database focuses on an array
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of molecules, including Class I MHCs (22) and TCRs [23].
The entries are given as number and type of MHC mole-
cules, number of MHC-peptide complexes or abundance
of peptides associated with each MHC serotype, generally
defined by mass spectroscopy. The entries list the cell type,
the antibody bound to the MHC and, if appropriate, the
binding epitope. This only applies to the number of
MHC-peptide complexes and the abundance of peptides
associated with each MHC.
Searching the database
Search mechanisms within AntiJen are significantly
improved and allow either a detailed or a broad search
from a simple user interface. From our experience with
JenPep, we recognize that accessibility to the data in a user
friendly manner is a vital requirement, and have
improved our current search mechanisms and developed
new search interfaces. Two different search mechanisms
are available. One is based on BLAST [24] and the other is
a bespoke system, allowing several alternative searches.
Within a typical search, the user-entered search criteria are
carried from an HTML form to a category specific PERL/
SQL script, which performs the database queries.
The BLAST search allows querying of a peptide or nucle-
otide sequence against the proteins contained in AntiJen;
all entries containing data within AntiJen which are rele-
vant to a protein sequence are linked via the BLAST out-
put. A local database of protein sequences is searched with
BLASTP or BLASTX [24] using the BLOSUM64 matrix. All
BLAST control variables are fixed. An HTML Front-End
(Figure 2), where a sequence can be entered or uploaded,
connects to a web server-based PERL/CGI scripts, which
interacts with BLAST. An annotated version of the default
BLAST output is produced and links to AntiJen entries via
SWISS-PROT [12] accession codes, which act as a query
within a Keyword search. This allows AntiJen entries to be
viewed directly from the BLAST output.
At present, peptide string, keyword, and protein name
index searches are available within the bespoke system,
which allows querying of individual peptide sequences or
at the level of whole protein antigens. An overview of the
AntiJen search systems is given in Figure 2 and 3. Epitopes,
MHC, TCR, TAP peptide binding and kinetics databases
can all be searched using sequence strings. The search pro-
tocol first returns an epitope list and a count of epitope
matches. Subsequently, experimental criteria can be
accessed for each selected epitope. Peptides can be
searched using an amino acid orientated query: a sparse
peptide string, similar in form to a peptide binding motif
[3] or a PROSITE pattern [25], is used to identify all
matching sequences. See Figure 4. Alternately, a list of pro-
tein antigens within AntiJen can be searched using key-
words; the thermodynamic binding data such as MHC-
peptide, TCR-pMHC and TAP, plus the B and T cell
archives, related to the search criteria can then be selected
from the matches based upon the SWISS-PROT accession
codes [12], displaying all corresponding entries in the
database.The other search method, allows the IPPI, diffu-
sion co-efficients, peptide libraries, antibody-protein and
copy number sub-databases to be searched using an index
Overview of the different search methods within AntiJen Figure 2
Overview of the different search methods within 
AntiJen. The example search is focused upon an MHC lig-
and. The MHC ligand data can be searched directly (A) from 
a link on the AntiJen homepage, a broad search and specific 
search is available. A search for the epitope AMALLRLPLV, 
has one hit (D), this leads to the entry (G). All of the other 
sub-databases can be searched in this manner from the 
homepage. The two other searches are more generalised. A 
Keyword search (B) carries out a broad search on the whole 
database, for the criteria – Bacteria. This search gives 139 
hits (E) and all of the sub-database entries can be selected 
from this output. The final search method is a BLAST search 
(C). The peptide (or nucleotide) sequence is queried against 
a local protein database. The output (F) provides links to the 
sub-databases relative to the protein.Immunome Research 2005, 1:4 http://www.immunome-research.com/content/1/1/4
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method, within a user-friendly HTML drop-down menu.
Each of these methods can also be moderated using sub-
sidiary search filters, data size ranges, and result
presentation alternatives, such as peptide length or IC50
values. Minimum and maximum values can be used to
restrict results, as can selection of MHC restriction alleles.
Discussion
The name given to our new database, AntiJen, reflects a
shift from a peptide orientated database structure, which
was inherent within our earlier JenPep database, to one
which can properly balance its focus on both protein anti-
gens and isolated peptides. As such, it represents an
important, integrated, immunological data resource. Ant-
iJen now provides broad insight into both T cell and B cell
mediated antigen recognition. In addition, through the
auspices of the IPPI sub-database, the database also
throws light on co-stimulation by co-receptors and gives
important insights into the innate immune response. Our
approach to protein-protein interactions, focusing on
measured affinities, complements other methods, such as
the Yeast-2-Hybrid system, which, while giving greater
volumes of data, has problems of accuracy [26]. This,
while not devoid of experimental artifact, gives a usefully
different perspective on cataloguing protein-protein
interactions. The further addition of weak binding nota-
tion to the MHC-peptide and TAP provides a greater over-
view of the nature of antigenic epitopes. This is further
improved by the addition of the peptide libraries data-
base, whereby key peptide residues can be highlighted.
New databases have expanded the breadth of AntiJen to
include biophysical data such as diffusion co-efficients
and cellular data such as abundance of molecules. The
antibody-antigenic protein sub-database will also provide
a key resource for in vivo and in vitro studies, aiding in the
selection of antibodies and peptide/protein targets.
AntiJen distinguishes itself from the other specific binding
databases [2-8] in several ways. Firstly, more data is
recorded; our MHC-peptide database contains over 2,000
more entries than MHCPEP [2] and 10,000 more entries
than EPIMHC [7]. Additionally, we have not restricted our
archive to only high binders or to a specific category, as
seen in EPIMHC and the HIV sequence databases [5]. Fur-
thermore, AntiJen is currently a curated database, which is
constantly expanding.
Searchable database types within AntiJen Figure 3
Searchable database types within AntiJen. The data-
base contains 3 types of searchable sub database: a set of 
Antigens searchable by keyword, various databases of func-
tional and thermodynamic data searchable by peptide 
sequence, and a database of immunological protein-protein 
interactions searchable through an index. Peptide sequence 
searches can be explicit or "motif" based. Searches can also 
be focussed by setting the value ranges for properties, such 
as IC50 etc, recorded in the databases. Currently there is a 
link between all the thermodynamic and kinetic databases 
and between them and the database of antigens. Only anti-
gens with data in one of the other sub-databases are included 
in the antigen database. Links to external databases are also 
indicated. The BLAST search provides an overall search of 
the databases except the Protein-Protein Interactions 
archive.
Sparse peptide sequence search Figure 4
Sparse peptide sequence search. Examples of the two 
search types available in AntiJen: (Search 1) a substring query 
and (Searches 2 and 3) PROSITE-like sparse queries allowing 
sets of variable (indicated by asterisks) and alternative 
(encased in square brackets) amino acids in the search. In our 
example, each query is an extension of the previous search. 
The initial search type returns a single hit, which is a weak 
binder. By introducing variable amino acid positions within 
the query string, the second query permits access to a larger 
data set with 39 hits being returned. The third search utilises 
both variable and alternative amino acid request functionality 
and returns 1996 hits. The number of entries returned can 
be reduced by specifying the epitope length, limiting IC50 val-
ues and restricting by one MHC allele. This search is con-
strained to peptides of amino acid length 9, which returns 
280 hits. Constraining further by MHC allele HLA-A*0201, 
reduces this to 120. An additional constraint using the IC50 
data filter, and requesting values below 500 only (the epitope 
range), reduces this again to 60.Immunome Research 2005, 1:4 http://www.immunome-research.com/content/1/1/4
Page 11 of 12
(page number not for citation purposes)
Most obviously, AntiJen is useful in the design of epitope
and subunit vaccines. Additionally, AntiJen is helpful in
the design of clinical diagnostics and other laboratory rea-
gents, such as the selection of peptides for tetramer design.
AntiJen is also useful in the parameterization of mathe-
matical models in theoretical immunology [27]. The rede-
velopment of the database has focused not only on
content, but also on infrastructure. The current system,
based on epitope string, keyword and index searches,
along with an overall BLAST search, plus the redesigned
HTML interface, leads to much greater accessibility and
usability. Finally, the database acts as a repository of
quantitative, continuous data, for the development of
data-driven in silico predictive models, such as prediction
of epitopes and MHC binding [18,19,28,29] through
QSAR modeling.
Future work
Future tasks in the development of AntiJen, fall into two
principle categories: eliminating deficiencies, errors, and
inconsistencies within the database and simultaneously
reinforcing it by expanding its depth, breadth, and scope.
We also need to monitor updates within external data-
bases, so that any alterations are mirrored within the
archive. Like all other such repositories, AntiJen is prone
to both systematic and random errors within the data
accumulation process. User feedback and our interactions
with immunologists will hopefully address persisting
errors. Deficiencies in our database include our current
inability to encode chemically or post-translationally
modified peptides, non-natural MHC mutants and non-
amino acid peptidomimetic MHC ligands. Additionally, it
would also be interesting to complement our existing data
on TAP binding with information on antigen presentation
pathways, such as proteasomal and cathepsin cleavage
patterns. Moreover, the compilation of B cell or antibody
epitope data is an area ripe for robust development. Linear
and conformational B cell epitopes are very much larger in
number than our current compilation, leaving us scope to
greatly increase recorded epitopes.
Conclusion
The development of a database is always a work in
progress. Not simply because the easily accessible litera-
ture is typically always increasing, but also because of the
desire to capture as much of the existing, but hidden, lit-
erature, as possible. In the post-genomic era, the database
has formed the bedrock and language of bioinformatics;
increasingly databases are coming to underpin our mod-
ern understanding of biology as a whole. Traditionally,
databases have arisen as a response to need, answering the
individual and idiosyncratic questions posed by biolo-
gists. However, the history of bioinformatics databases
has shown the extraordinarily diverse ways in which
archived data can be used.
In creating AntiJen, we were motivated partly by our
desire, and the desire of collaborators, to use the data
within it to build predictive in silico models [16,17,28,29],
and partly by a more altruistic desire to generate a useful,
integrated database system with a quantitative focus. Ant-
iJen has many potential uses throughout the immunolog-
ical discipline, from immunoinformaticans to
experimental immunologists and vaccinologists. By
increasing the degree to which data is machine readable
and web accessible, we open up new, and previously
unthought-of, avenues for the bioinformatic exploration
of immunological data.
AntiJen is a primary data resource, amongst the most com-
plete of its kind, yet, like SWISSPROT [12] or GenBank
[30] decades ago, it is still relatively small and offers much
scope for improved annotation. We see the database as a
foundation from which to consolidate, through time, thus
achieving a comprehensive resource of immunological
data.
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